JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population
Rostami R, Aghasi MR, Mohammadi A, Nourooz-Zadeh J (2013) Enhanced oxidative stress in Hashimotos thyroiditis: inter-relationships to biomarkers of thyroid function
This is the perfect \u201cnewbie\u201d aesthetic treatment because of that
Blockbuster GLP-1 Therapies Dominating the Global Market The global GLP-1 market is led by Novo Nordisk and Eli Lilly, with blockbuster drugs like Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound) driving multi-billion dollar sales
Antibiotic causes include sulfonamides and, less often, fluoroquinolones and minocycline
Access to a supportive community This community connects you with other Found members for motivation and accountability